- Total Q3 revenue dropped 5% year-over-year to $381.4M (product revenue $323.8M).
- Q3 GAAP EPS was $(0.27) vs $(0.50) YoY; Non-GAAP EPS reached $0.13 vs $(0.13) YoY.
- YTD revenue declined 14% to $1.51B from $1.76B in the prior-year period.
Signal #150140 · SEC 8-K
$SRPT SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $SRPT filing catalyst
Why did $SRPT trigger an AI stock catalyst alert?
$SRPT triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Sarepta Therapeutics Reports Q3 Total Revenue Down 5% to $381.4M. Key points: - Total Q3 revenue dropped 5% year-over-year to $381.4M (product revenue $323.8M). - Q3 GAAP EPS was $(0.27) vs $(0.50) YoY; Non-GAAP EPS reached $0.13 vs $(0.13) YoY. - YTD revenue declined 14% to $1.51B from $1.76B in the prior-year period.
How did $SRPT stock react after the SEC filing?
After the SEC 8-K for $SRPT, observed market reaction: T0 price $17.57. Past moves do not guarantee future results.
Where can I get real-time $SRPT SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $SRPT via Telegram and the VIP Web Terminal from €10/month.